How to appeal a Premera Blue Cross diabetes drugs & insulin denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal a Premera Blue Cross diabetes drugs & insulin denial, file an internal appeal within 180 days of the date on the denial letter through Premera Blue Cross's member or provider portal, under ACA §2719 + ERISA §503. Premera Blue Cross returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
What Premera Blue Cross's policy requires for diabetes drugs & insulin
Cited policy: BCBS External Insulin Infusion Pump Medical Policy (mirrors Medicare LCD L33464)
T1D OR insulin-requiring T2D meeting C-peptide / functional criteria; ≥3 injections/day or basal-bolus regimen; SMBG ≥4×/day or CGM; recent A1c documented; trained on pump.
How Premera Blue Cross denies diabetes drugs & insulin — and how to counter it
Where Premera Blue Cross pushes back: 1) Patient is Type 2 — pump not covered; 2) C-peptide above threshold; 3) No documentation of MDI failure.
Counter-arguments that hold up: LCD L33464 explicitly includes T2D meeting functional criteria (insulin deficiency, MDI ≥3/day, hypoglycemia, dawn phenomenon). ADA §7.20 supports CSII in selected T2D. Cite C-peptide value in fasting state with concurrent glucose.
What Premera Blue Cross typically denies for diabetes drugs & insulin
Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For diabetes drugs & insulin, expect:
- WA-specific mental health parity violations
- Step therapy via Express Scripts
- Out-of-network reductions
- Specialty drug prior auth
Treatments most often denied in this category
These are the diabetes drugs & insulin treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Rapid-acting analog insulin
- Basal analog insulin
- Pre-mixed insulin
- Concentrated insulin
- GLP-1 for T2D
- DPP-4 inhibitor
How to submit the appeal to Premera Blue Cross
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
- File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Premera Blue Cross diabetes drugs & insulin denial?
Premera Blue Cross allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Premera Blue Cross appeal?
Members can submit through the Premera Blue Cross member portal at https://www.premera.com. Providers should use the provider portal at https://www.premera.com/wa/provider. Faxed and mailed appeals are accepted but take longer.
What denials does Premera Blue Cross most often issue for diabetes drugs & insulin?
For diabetes drugs & insulin, Premera Blue Cross most often denies on: 1) Patient is Type 2 — pump not covered; 2) C-peptide above threshold; 3) No documentation of MDI failure. The strongest counters: LCD L33464 explicitly includes T2D meeting functional criteria (insulin deficiency, MDI ≥3/day, hypoglycemia, dawn phenomenon). ADA §7.20 supports CSII in selected T2D. Cite C-peptide value in fasting state with concurrent glucose.
What if Premera Blue Cross denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
- Premera Blue Cross glp-1 weight-loss drugs denial
- Premera Blue Cross mental health & behavioral health denial
- Premera Blue Cross fertility & ivf denial
- Premera Blue Cross adult adhd medications denial
- UnitedHealthcare diabetes drugs & insulin denial
- Elevance Health diabetes drugs & insulin denial
- Aetna diabetes drugs & insulin denial
Start your Diabetes drugs & insulin appeal
Upload your Premera Blue Cross denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com